J
Jiang Shou
Researcher at Baylor College of Medicine
Publications - 12
Citations - 3408
Jiang Shou is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Estrogen receptor & Tamoxifen. The author has an hindex of 10, co-authored 12 publications receiving 3246 citations.
Papers
More filters
Journal ArticleDOI
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Jiang Shou,Suleiman Massarweh,C. Kent Osborne,A. E. Wakeling,Simale Ali,Heidi L. Weiss,Rachel Schiff +6 more
TL;DR: Gefitinib pretreatment eliminated tamoxifen's agonist effects, restored its antitumor activity both in vitro and in vivo in MCF-7/HER2-18 cells, and revealed molecular cross-talk between the ER and HER2 pathways was increased.
Journal ArticleDOI
Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase
M. Carolina Gutierrez,Simone Detre,Stephen S. Johnston,Syed K. Mohsin,Jiang Shou,D. Craig Allred,Rachel Schiff,C. Kent Osborne,Mitch Dowsett +8 more
TL;DR: C Crosstalk between ER, HER-2, p38, and ERK may contribute to tamoxifen resistance and may provide molecular targets to overcome this resistance.
Journal ArticleDOI
Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance
TL;DR: A strategy of combining endocrine therapy (particularly tamoxifen) with these inhibitors, to circumvent de novo and acquired resistance, will be discussed.
Journal Article
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
TL;DR: Although estrogen deprivation therapy is often effective in ER-positive breast cancer, de novo and acquired resistance are still problematic, as trials of aromatase inhibitors show superior results compared with tamoxifen, especially in tumors overexpressing HER2.
Journal Article
Breast Cancer Endocrine Resistance How Growth Factor Signaling and Estrogen Receptor Coregulators Modulate Response
TL;DR: Failure of the antitumor activity of tamoxifen in patients with breast cancer is actually determined by both the levels of and the interaction between the ER coactivator amplified in breast cancer-1 and the epidermal growth factor-related protein HER.